Watch Out For These Indian Pharma Stocks To Be Impacted By The U.S' Biosecure Act

In a significant development for the global pharmaceutical industry, the US has enacted the Biosecure Act, which bans American companies from partnering with specific Chinese biotech firms. The primary goal of this legislation is to prevent potential misuse of US genomic data, prompting a major shift in the pharmaceutical supply chain. The ban targets major players like BGI Genomics, MGI Tech, Complete Genomics, WuXi AppTec, and WuXi Biologics, pushing US drugmakers to look towards alternative suppliers. This new law is set to create a ripple effect across the industry, and could particularly benefit Indian contract development and manufacturing organisation companies. India’s CDMO sector, which currently holds just 2.7% of the global market, could see substantial growth. With China’s CDMO industry dominating 8% of the global market, this change represents a significant opportunity for Indian companies to challenge China’s stronghold and expand their share.

#stockmarket #stockmarketnews #pharma